Alteogen Enters Option and License Agreement with Novartis for Development and Commercialization of Hybrozyme™-Enabled Subcutaneous Products
Novartis obtains rights to develop and commercialize subcutaneous formulations for multiple products utilizing ALT-B4 Alteogen's fourth licensing agreement signed this year further accelerating the expansion of the Hybrozyme™ platform DAEJEON, South Korea, Sept. 2, 2026 /PRNewswire/ --...
Covered in this story
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.